Clinical Trial Update: BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BI 655066 to placebo and active comparator (ustekinumab) in moderate to severe chronic plaque psoriasis has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BI 655066
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-07-15